In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AM­RN were blitzed Mon­day evening, los­ing bil­lions in val­ue as re­ports spread that the com­pa­ny had lost its high-pro­file ef­fort to keep its Vas­cepa patents pro­tect­ed from gener­ic drug­mak­ers.

Amarin had been fight­ing to keep key patents un­der lock and key — and away from gener­ic ri­vals — for an­oth­er 10 years, but Dis­trict Court Judge Mi­ran­da Du in Las Ve­gas ruled against the biotech. She ruled that:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.